title: Success rates of mineral trioxide aggregate, ferric sulfate, and formocresol pulpotomies: a 24-month study.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the total success rates of mineral trioxide aggregate (MTA), ferric sulfate (FS), and formocresol (FC) as pulpotomy agents in primary molars.
  
  
  METHODS
  A randomized, split-mouth study design was used in 32 healthy 5- to 7-year-old children with 128 carious primary molars without clinical or radiographic evidence of pulp degeneration. The pulpotomy agents were assigned as follows: Group 1=MTA; Group 2=FS; Group 3=1:5 diluted Buckley's FC; and Group 4=zinc oxide eugenol (ZOE) base. Clinical and radiographic follow-up at 6, 12, and 24 months used the following criteria: pain; swelling; sinus tract; mobility; internal root resorption; and furcation and/or periapical bone destruction. The data were analyzed using chi-square.
  
  
  RESULTS
  No significant differences in success rates were found among the groups at 6 and 12 months. Success rates in groups 1 to 4 at 24 months were 96%, 88%, 88%, and 68% respectively. There was a significant difference (P<.001) between the MTA and ZOE groups at 24 months.
  
  
  CONCLUSIONS
  ZOE, as the only pulpotomy medicament, had a significantly lower success rate than MTA. No significant differences were observed, among the 3 experimental materials (MTA, FC, and FS) at 2 years follow-up.
authors.affiliation: Department of Pedodontics, Istanbul University, Istanbul, Turkey.
authors.forename: Arzu Pinar
authors.initials: AP
authors.lastname: Erdem
authors.forename: Yeliz
authors.initials: Y
authors.lastname: Guven
authors.forename: Beyza
authors.initials: B
authors.lastname: Balli
authors.forename: Banu
authors.initials: B
authors.lastname: Ilhan
authors.forename: Elif
authors.initials: E
authors.lastname: Sepet
authors.forename: Isin
authors.initials: I
authors.lastname: Ulukapi
authors.forename: Oya
authors.initials: O
authors.lastname: Aktoren
mesh_terms: D017607:Aluminum Compounds / Q000627:therapeutic use*; D017610:Calcium Compounds / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003723:Dental Amalgam; D003731:Dental Caries / Q000628:therapy; D003751:Dental Fistula / Q000209:etiology; D003793:Dental Restoration, Permanent / Q000379:methods; D004338:Drug Combinations; D004487:Edema / Q000209:etiology; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005566:Formocresols / Q000627:therapeutic use*; D017823:Furcation Defects / Q000209:etiology; D006801:Humans; D008297:Male; D008963:Molar / Q000187:drug effects; D010087:Oxides / Q000627:therapeutic use*; D010483:Periapical Diseases / Q000209:etiology; D057872:Pulp Capping and Pulpectomy Agents / Q000627:therapeutic use*; D011672:Pulpotomy / Q000379:methods*; D012391:Root Resorption / Q000209:etiology; D017640:Silicates / Q000627:therapeutic use*; D016037:Single-Blind Method; D014086:Tooth Mobility / Q000209:etiology; D014094:Tooth, Deciduous / Q000187:drug effects; D014098:Toothache / Q000209:etiology; D016896:Treatment Outcome; D015035:Zinc Oxide-Eugenol Cement / Q000627:therapeutic use
chemical_list: D017607:Aluminum Compounds; D017610:Calcium Compounds; D004338:Drug Combinations; D005290:Ferric Compounds; D005566:Formocresols; D010087:Oxides; D057872:Pulp Capping and Pulpectomy Agents; D017640:Silicates; D015035:Zinc Oxide-Eugenol Cement; C086631:mineral trioxide aggregate; C031025:formocresol; C024823:ferric sulfate; D003723:Dental Amalgam